In this issue of The Lancet Psychiatry, Benjamin Perry and colleagues1 present a collaboratively developed, refined, and externally validated risk prediction tool (the Psychosis Metabolic Risk Calculator [PsyMetRiC]) that is clinically available, and that can separately predict the risk of clinically significant weight gain, metabolic syndrome, and type 2 diabetes in young people with psychosis. Key to the collaborative development of PsyMetRiC has been the involvement of young people with a lived experience of psychosis, supported by the McPin Foundation and Equally Well UK.
Radically different